España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Cyclacel Pharmaceuticals
CYCCP
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$8.33
1.39
20.03%
After Hours: Apr 29, 5:32 PM EDT
Get Report
Comment
Cyclacel Pharmaceuticals (CYCCP) Forecast
News
Earnings
Cyclacel Pharmaceuticals (CYCCP) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Cyclacel Pharmaceuticals (NASDAQ:CYCCP) Stock
Cyclacel Pharmaceuticals Stock (NASDAQ: CYCCP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 13, 2024
Cyclacel Pharmaceuticals Announces Exercise O...
Benzinga Newsdesk
Tuesday, November 12, 2024
Cyclacel Pharmaceuticals shares are trading h...
Benzinga Newsdesk
Wednesday, October 09, 2024
Cyclacel Pharmaceuticals To Present New Clini...
Benzinga Newsdesk
Friday, October 04, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Tuesday, June 04, 2024
Cyclacel's Fadraciclib Reports Efficacy In Pa...
Benzinga Newsdesk
Monday, June 03, 2024
Cyclacel Pharmaceuticals To Present Clinical ...
Benzinga Newsdesk
Friday, April 12, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Monday, April 01, 2024
Cyclacel Pharmaceuticals To Present New Clini...
Benzinga Newsdesk
Thursday, March 07, 2024
Cyclacel Pharmaceuticals Announces Preclinica...
Benzinga Newsdesk
Wednesday, March 06, 2024
Cyclacel Pharmaceuticals Announces Receipt Of...
Benzinga Newsdesk
Thursday, January 11, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Friday, December 22, 2023
Cyclacel Pharmaceuticals Announces $1.3M Regi...
Benzinga Newsdesk
Monday, December 18, 2023
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B And MTAP Deletions
Happy Mohamed
Thursday, November 30, 2023
Cyclacel Regains Compliance With Nasdaq Listi...
Benzinga Newsdesk
Thursday, November 09, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Thursday, November 02, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Friday, June 02, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Wednesday, May 17, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Wednesday, May 03, 2023
Cyclacel Pharmaceuticals Announces Receipt of $4.7M R&D Tax Credit
Charles Gross
Thursday, January 05, 2023
Cyclacel Pharmaceuticals Reviews 2022 Achieve...
Benzinga Newsdesk
Wednesday, October 26, 2022
Cyclacel Reports Preliminary Data From Phase ...
Benzinga Newsdesk
Thursday, October 13, 2022
Cyclacel Pharmaceuticals To Present Prelimina...
Benzinga Newsdesk
Wednesday, June 08, 2022
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Tuesday, April 19, 2022
Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Cyc140 In Patients With Advanced Solid Tumors And Lymphomas
Bill Haddad
Tuesday, April 12, 2022
Cyclacel Pharmaceuticals Announces Publicatio...
Benzinga Newsdesk
Wednesday, February 02, 2022
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Friday, November 05, 2021
Cyclacel Announces Dosing Of First Patient In...
Benzinga Newsdesk
Thursday, November 04, 2021
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Friday, October 22, 2021
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Monday, August 09, 2021
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Tuesday, July 13, 2021
Cyclacel Announces Dosing of First Patient in...
Benzinga Newsdesk
Friday, May 28, 2021
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Friday, May 21, 2021
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Wednesday, May 19, 2021
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Monday, March 15, 2021
Cyclacel To Present At Oppenheimer 31st Annua...
Benzinga Newsdesk
Friday, March 12, 2021
Cyclacel Pharmaceuticals Prices 1,807,143 Sha...
Benzinga Newsdesk
Monday, January 11, 2021
Cyclacel Pharmaceuticals Announces Key Busine...
Benzinga Newsdesk
Tuesday, January 05, 2021
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Monday, October 26, 2020
Cyclacel Presents Phase 1 Clinical Data Showi...
Benzinga Newsdesk
Wednesday, October 07, 2020
11 Healthcare Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Monday, September 21, 2020
Cyclacel Announces Fadraciclib Abstract Selec...
Benzinga Newsdesk
Monday, July 13, 2020
Cyclacel's Highlights Publication Of Peer-Rev...
Benzinga Newsdesk
Monday, July 22, 2019
Cyclacel Pharmaceuticals Announces First Pati...
Benzinga Newsdesk
Monday, April 01, 2019
Cyclacel Pharma Give an Updated From Phase 1 ...
Benzinga Newsdesk
Tuesday, October 23, 2018
Stocks Which Set New 52-Week Low Yesterday, O...
Benzinga Newsdesk
Monday, September 24, 2018
Stocks Which Set New 52-Week Low Friday, Sept...
Benzinga Newsdesk
Monday, April 16, 2018
Cyclacel Reports Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Benzinga
Thursday, September 17, 2015
Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas
Benzinga
Thursday, July 02, 2015
Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,
Benzinga
Monday, June 29, 2015
Cyclacel & ManRos Therapeutics Reports Licensing, Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis
Benzinga
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
